| Symbol | BEAM |
|---|---|
| Name | BEAM THERAPEUTICS INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Address | 238 MAIN STREET, CAMBRIDGE, Massachusetts, 02142, United States |
| Telephone | +1 857 - 327-8775 |
| Fax | — |
| — | |
| Website | https://www.beamtx.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | — |
| Description | Beam Therapeutics Inc is a biotechnology company engaged in creating genetic medicines based on its base editing technology. This technology enables a new class of genetic medicines that targets a single base in the genome without making a double-stranded break in the DNA. The companys portfolio comprises Gene Correction, Gene Modification, Gene Activation, Gene Silencing, and Multiplex Editing. Additional info from NASDAQ: |
New Form ARS - Beam Therapeutics Inc. <b>Filed:</b> 2026-04-17 <b>AccNo:</b> 0001193125-26-161561 <b>Size:</b> 1 MB
Read moreNew Form DEFA14A - Beam Therapeutics Inc. <b>Filed:</b> 2026-04-17 <b>AccNo:</b> 0001193125-26-161541 <b>Size:</b> 1 MB
Read moreNew Form DEF 14A - Beam Therapeutics Inc. <b>Filed:</b> 2026-04-17 <b>AccNo:</b> 0001193125-26-161512 <b>Size:</b> 4 MB
Read more📋 CAROLE HO (Director) plans to sell 88K shares of BEAM THERAPEUTICS INC. (at $30.73 each, total $2.7M) Filed: Apr 14, 2026 | ID: 003430
Read moreEvans John M. 🔴 sold 30.1K shares of Beam Therapeutics Inc. (BEAM) at $24.58 Transaction Date: Apr 01, 2026 | Filing ID: 144086
Read moreSimon Amy 🔴 sold 6.7K shares of Beam Therapeutics Inc. (BEAM) at $24.58 Transaction Date: Apr 01, 2026 | Filing ID: 144080
Read moreCavanagh Bethany J 🔴 sold 3.2K shares of Beam Therapeutics Inc. (BEAM) at $24.58 Transaction Date: Apr 01, 2026 | Filing ID: 144068
Read moreBellon Christine 🔴 sold 6.0K shares of Beam Therapeutics Inc. (BEAM) at $24.58 Transaction Date: Apr 01, 2026 | Filing ID: 144067
Read moreCiaramella Giuseppe 🔴 sold 11.8K shares of Beam Therapeutics Inc. (BEAM) at $24.58 Transaction Date: Apr 01, 2026 | Filing ID: 144054
Read moreBellon Christine 🟢 acquired 20.0K shares of Beam Therapeutics Inc. (BEAM) Transaction Date: Mar 31, 2026 | Filing ID: 140586
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07304791 | This is a Phase 1, Randomized, Single-blind, Placebo-controlled Study to Assess… | Phase1 | Healthy Subjects | Recruiting | 2025-10-27 | 2026-05-29 | ClinicalTrials.gov |
| NCT07183735 | A Crossover Trial to Examine the Efficacy of a Powder to Improve Sleep Quality … | Na | Sleep | Completed | 2024-07-02 | 2024-10-17 | ClinicalTrials.gov |
| NCT05885464 | A Study Evaluating the Safety and Efficacy of BEAM-201 in Relapsed/Refractory T… | Phase1 | Lymphoblastic Lymphoma | Active_Not_Recruiting | 2023-05-25 | 2026-12-01 | ClinicalTrials.gov |
| NCT05521243 | An Exploratory Investigation of a Supplement to Enhance Sleep Quality and Quant… | Na | Sleep | Completed | 2022-05-09 | 2022-09-30 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Long-Term Follow-up Study of patients who received BEAM-101 | DRUG | Preclinical | Hemoglobinopathy | RECRUITING | NCT07373639 |
| Placebo Comparator | DRUG | Phase PHASE1 | Healthy Subjects | RECRUITING | NCT07304791 |
| BEAM-103 | DRUG | Phase PHASE1 | Healthy Subjects | RECRUITING | NCT07304791 |
| Allogeneic anti-CD7 CAR-T cells (BEAM-201) | BIOLOGICAL | Phase PHASE1 | T-Cell Acute Lymphoblastic Leukemia/Lymphoma | RECRUITING | NCT06934382 |
| BEAM-301: Single dose of BEAM-301 administered by IV | DRUG | Phase PHASE1 | Glycogen Storage Disease Type Ia | RECRUITING | NCT06735755 |
| BEAM-302 | DRUG | Phase PHASE1 | Alpha 1-Antitrypsin Deficiency | RECRUITING | NCT06389877 |
| Biologic Specimen Collection | OTHER | Preclinical | Sickle Cell Trait | RECRUITING | NCT06071377 |
| BEAM-201 | BIOLOGICAL | Phase PHASE1 | Lymphoblastic Lymphoma | ACTIVE_NOT_RECRUITING | NCT05885464 |
| BEAM-101 | BIOLOGICAL | Phase PHASE1 | Sickle Cell Disease | ACTIVE_NOT_RECRUITING | NCT05456880 |